Screener
Janux Therapeutics JANX Q2 2026 earnings
Reported August 6, 2026 · After market close
Revenue$10.3MMiss by $8.8M
EPS-$0.35Miss by $0.10
Revenue estimate$19.1M
EPS estimate-$0.25
“Enrollment continues across our prostate cancer programs, including JANX007 and JANX014, and we remain on track to initiate clinical development of JANX013 later this year. We also continue to make progress with JANX011 in healthy volunteers as we advance our autoimmune disease pipeline.”
Next report
Nov 5, 2026 (in 2 months)Revenue estimate$8.0M
EPS estimate-$0.45
Financials
Q2 2026Valuation & ratios
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Janux Therapeutics report Q2 2026 earnings?
- Janux Therapeutics (JANX) reported Q2 2026 earnings on August 6, 2026 after market close.
- What were Janux Therapeutics's Q2 2026 revenue and EPS?
- Janux Therapeutics reported revenue of $10.3M and eps of $-0.35 for Q2 2026.
- Did Janux Therapeutics beat estimates in Q2 2026?
- Revenue missed the consensus estimate of $19.1M by $8.8M. EPS missed the consensus estimate of $-0.25 by $0.10.
- How did Janux Therapeutics's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 36.4% from $-0.55.
- Where can I find Janux Therapeutics's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-337977) and the 10-Q periodic report (0001193125-26-338078) directly on SEC EDGAR. The filing index links above go to sec.gov.
